Quantisnow Logo
Dashboard

CONMED Corporation Announces Quarterly Cash Dividend

$CNMD
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Get the next $CNMD alert in real time by email

CONMED Corporation (NYSE:CNMD) announced today that its Board of Directors declared a quarterly cash dividend of $0.20 per share on May 22, 2024, payable on July 5, 2024, to all shareholders of record as of June 14, 2024.

About CONMED Corporation

CONMED is a medical technology company that provides surgical devices and equipment for minimally invasive procedures. The Company's products are used by surgeons and physicians in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit www.conmed.com.

Forward-Looking Statements

This press release may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to the risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2023, listed under the heading Forward-Looking Statements in the Company's most recently filed Form 10-Q and other risks and uncertainties, which may be detailed from time to time in reports filed by CONMED with the SEC. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company's performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management's expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct

Get the next $CNMD alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CNMD

DatePrice TargetRatingAnalyst
2/6/2025$85.00 → $70.00Overweight → Neutral
Analyst
2/1/2024$119.00 → $129.00Buy
Needham
5/22/2023$140.00Buy
CL King
3/27/2023$124.00Sector Weight → Overweight
KeyBanc Capital Markets
3/21/2023$96.00Equal Weight
Wells Fargo
10/12/2022$85.00Hold
Jefferies
3/2/2022$155.00Neutral
BofA Securities
1/21/2022$158.00 → $150.00Buy
Needham
More analyst ratings

$CNMD
 Press Releases

Fastest customizable press release news feed in the world

See more

  • CONMED Corporation to Announce First Quarter 2025 Financial Results on April 30, 2025

    CONMED Corporation (NYSE:CNMD) today announced that it will report financial results for the first quarter 2025 after the market close on Wednesday, April 30, 2025. The Company's management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed from the "Investors" section of CONMED's website at www.conmed.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call. About CONMED Corporation CONMED is a medical t

    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

  • CONMED Corporation Adds Mark Kaye to its Board of Directors

    CONMED Corporation (NYSE:CNMD) today announced that Mark Kaye will be joining its Board of Directors effective February 24th, 2025. "My fellow directors and I are extremely pleased to welcome Mark to the board," said Martha Goldberg Aronson, Chair of CONMED's Board of Directors. "Mark brings a wealth of experience to CONMED, including deep knowledge across finance, accounting, risk management, strategic planning, and operational efficiencies. He also brings a strong background and expertise in both corporate governance and healthcare. Mark's skills and insights will help guide CONMED's future direction." "Mark is an outstanding addition to our board," said Patrick Beyer, President and C

    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

  • CONMED Corporation Announces Quarterly Cash Dividend

    CONMED Corporation (NYSE:CNMD) announced today that its Board of Directors declared a quarterly cash dividend of $0.20 per share on February 24, 2025, payable on April 4, 2025, to all shareholders of record as of March 14, 2025. About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit www.conmed.com. Forward-Looking Statements This press release may contain forward-looking statements based on

    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

$CNMD
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$CNMD
 Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$CNMD
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$CNMD
 SEC Filings

See more

$CNMD
 Leadership Updates

Live Leadership Updates

See more

  • Beta Bionics Announces the Appointment of Martha Goldberg Aronson as Chair of Its Board of Directors

    CONCORD, Mass.--(BUSINESS WIRE)--Beta Bionics, Inc., a medical technology company focused on the design, development, and commercialization of the iLet® bionic pancreas system, today announced the appointment of Martha Goldberg Aronson as Chair of its Board of Directors, effective immediately. Ms. Aronson, who joined the Beta Bionics Board as a Director in February of 2020, succeeds Ed Damiano, President and Chief Executive Officer of Beta Bionics, who has served as Chair since inception of the company in 2015. Dr. Damiano will remain a member of the Board while continuing to serve in his roles as President and Chief Executive Officer of Beta Bionics. “On behalf of the Board, I am

    $CSII
    $MEI
    $CNMD
    Medical/Dental Instruments
    Health Care
    Electrical Products
    Technology

$CNMD
 Financials

Live finance-specific insights

See more

  • CONMED Corporation to Announce First Quarter 2025 Financial Results on April 30, 2025

    CONMED Corporation (NYSE:CNMD) today announced that it will report financial results for the first quarter 2025 after the market close on Wednesday, April 30, 2025. The Company's management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed from the "Investors" section of CONMED's website at www.conmed.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call. About CONMED Corporation CONMED is a medical t

    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

  • CONMED Corporation Announces Quarterly Cash Dividend

    CONMED Corporation (NYSE:CNMD) announced today that its Board of Directors declared a quarterly cash dividend of $0.20 per share on February 24, 2025, payable on April 4, 2025, to all shareholders of record as of March 14, 2025. About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit www.conmed.com. Forward-Looking Statements This press release may contain forward-looking statements based on

    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

  • CONMED Corporation Announces Fourth Quarter and Full-Year 2024 Financial Results

    CONMED Corporation (NYSE:CNMD) today announced financial results for the fourth quarter and full-year ended December 31, 2024. Fourth Quarter 2024 Highlights Sales of $345.9 million increased 5.8% year over year as reported and 6.0% in constant currency. Domestic revenue increased 6.8% year over year. International revenue increased 4.4% year over year as reported and 5.0% in constant currency. Diluted net earnings per share (GAAP) were $1.08 compared to diluted net earnings per share (GAAP) of $1.05 in the fourth quarter of 2023. Adjusted diluted net earnings per share(1) were $1.34, an increase of 26.4% compared to the fourth quarter of 2023. Full-Year 2024 Highlights

    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

$CNMD
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more